# 04_QA_REPORT.md

# QA Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0230 |
| Population Package ID | PP-0230 |
| Title | Long-term Follow-up |
| Version | 1.0.0 |
| Status | Approved — GOLD |
| Decision State | Approved + Locked |
| QA Disposition | PASS |
| Integration Status | Ready for Integration |

---

# QA Scope

This QA review evaluates the completed PP-0230 Gold package across:

1. Content QA
2. Clinical QA
3. Educational QA
4. Governance QA

It additionally evaluates:

- Clinical Safety
- Patient Misconceptions
- Adjacent PP Overlap
- Evidence Traceability
- Numerical Evidence
- Knowledge Graph
- Gold Depth Integrity
- Source-First compliance
- Locked Decision integrity
- Cross-artifact consistency
- Package integrity.

QA is substantive and evidence-oriented rather than a checklist-only confirmation.

---

# Layer 1 — Content QA

## 1.1 Scope Compliance

**PASS**

The four artifacts consistently implement the approved PP-0230 identity:

> **Long-term Follow-up = the longitudinal continuity-of-care layer after gastric cancer treatment.**

The package does not redefine PP-0230 as:

- surveillance;
- recurrence detection;
- imaging;
- survivorship;
- treatment toxicity;
- recurrent disease management.

---

## 1.2 Included Content Completeness

**PASS**

The package covers:

- definition;
- purpose;
- temporal follow-up;
- clinical assessment;
- laboratory assessment;
- surveillance interface;
- recurrence interface;
- post-gastrectomy monitoring;
- five-year transition;
- primary-care coordination;
- care transition;
- patient records;
- patient-facing expectations;
- misconceptions;
- Knowledge Graph.

---

## 1.3 Exclusion Integrity

**PASS**

The package explicitly excludes:

- detailed surveillance algorithms;
- recurrence algorithms;
- RECIST;
- formal response assessment;
- imaging methodology;
- recurrent/metastatic treatment;
- detailed nutrition treatment;
- detailed toxicity management;
- detailed rehabilitation;
- individualized follow-up scheduling.

No major excluded domain was substantively absorbed into PP-0230.

---

## 1.4 Internal Consistency

**PASS**

The same conceptual distinction is maintained throughout:

**Follow-up**

≠

**Surveillance**

and:

**Follow-up**

interfaces with:

**Recurrence detection**

**Treatment-sequela monitoring**

**Survivorship**

**Routine medical care**

This distinction appears consistently in CKO, KP, EP and QA.

---

# Layer 2 — Clinical QA

## 2.1 Primary Guideline Verification

**PASS**

The principal disease-specific source is NCCN Gastric Cancer v2.2026.

The supplied NCCN file directly supports:

- GAST-7 follow-up/surveillance;
- H&P timing;
- clinically indicated CBC/chemistry;
- EGD/imaging according to treatment context;
- nutritional monitoring after surgical resection;
- follow-up beyond five years based on risk factors/comorbidities;
- lifelong post-gastrectomy nutritional monitoring;
- survivorship coordination.

The source search confirms these elements. fileciteturn40file1turn40file3turn40file4

---

## 2.2 Clinical Accuracy

**PASS**

No unsupported universal claim was introduced.

The package deliberately states that:

- exact follow-up varies;
- not every patient receives the same tests;
- five years is not equivalent to complete cessation of care;
- symptoms do not automatically indicate recurrence;
- individual decisions remain with the treating team.

---

## 2.3 Evidence-Maturity Accuracy

**PASS**

The package preserves NCCN's explicit statement that gastric-cancer surveillance recommendations are based on limited prospective evidence, retrospective literature and expert consensus. fileciteturn40file4

This prevents overstatement of certainty.

---

## 2.4 Post-gastrectomy Clinical Accuracy

**PASS**

The package accurately represents long-term post-gastrectomy needs.

NCCN specifically identifies lifelong monitoring for nutritional sequelae and lists potential deficiencies including vitamin B12, iron, zinc, calcium and vitamin D. fileciteturn40file1turn40file2

The package does not convert this into individualized supplementation instructions.

---

## 2.5 Survivorship Coordination

**PASS**

NCCN explicitly supports:

- lifelong primary-care relationship;
- defined oncology/PCP roles;
- subspecialty involvement;
- follow-up and surveillance information;
- post-treatment needs;
- timing of transfer of care when appropriate;
- periodic assessment of ongoing needs. fileciteturn40file2turn40file18

The package accurately translates this into a continuity-of-care model.

---

# Layer 3 — Educational QA

## 3.1 Patient-Facing Clarity

**PASS**

The package explains:

- follow-up;
- surveillance;
- recurrence;
- long-term effects;
- survivorship;
- primary care;

without assuming specialist knowledge.

---

## 3.2 Terminology

**PASS**

Technical concepts are introduced with contextual explanation.

Examples:

- H&P = history and physical examination;
- surveillance = structured assessment for cancer-related disease status;
- survivorship = long-term care after cancer diagnosis/treatment.

---

## 3.3 Logical Flow

**PASS**

The CKO follows a patient-centered sequence:

**Treatment completed**

→

**why follow-up continues**

→

**what happens during follow-up**

→

**how follow-up changes**

→

**what happens after five years**

→

**how long-term care is coordinated.**

---

## 3.4 Misconception Control

**PASS**

Major misconceptions are explicitly addressed:

- follow-up = scans;
- follow-up = surveillance;
- every symptom = recurrence;
- five years = end of healthcare;
- everyone has the same schedule;
- normal imaging = no further care.

---

# Layer 4 — Governance QA

## 4.1 Source-First Audit

**PASS**

PP-specific clinical Source Materials were searched before artifact production.

The NCCN v2.2026 file was specifically retrieved for:

- GAST-6;
- GAST-7;
- GAST-H;
- GAST-I.

Relevant evidence was also identified in supplied ESMO-ASCO and ACS materials. fileciteturn40file0turn40file2turn40file4turn39file13

---

## 4.2 Locked Decision Integrity

**PASS**

The artifact package follows the approved PP-0230 Decision Batch.

No substantive scope reopening occurred after approval.

---

## 4.3 Gold Structure Audit

**PASS**

Required artifacts are present:

```text
01_CKO.md
02_KNOWLEDGE_PASSPORT.md
03_PRIMARY_EVIDENCE_PACKAGE.md
04_QA_REPORT.md
```

The project specification requires all four components. fileciteturn41file4turn41file5

---

## 4.4 Gold Depth Integrity Review

**PASS — GOLD DEPTH PRESERVED**

The package was produced under the absolute Gold-depth rule.

The governing rule states that Gold Reference Depth is a minimum standard and prohibits:

- compacting;
- shortening;
- summarizing;
- collapsing sections;
- reducing evidence detail;
- reducing QA depth;
- reducing Knowledge Graph depth;
- reducing patient-facing depth. fileciteturn41file0turn41file3

The artifacts preserve:

- structured educational depth;
- evidence reasoning;
- evidence matrix;
- Knowledge Graph;
- boundary mapping;
- patient-facing explanation;
- misconception handling;
- substantive QA.

---

## 4.5 Evidence Traceability Audit

**PASS**

Major clinical claims are linked in the Evidence Package to source categories and specific NCCN sections.

The most consequential claims are directly anchored to:

- GAST-7;
- GAST-H;
- GAST-I.

---

## 4.6 Numerical Evidence Audit

**PASS**

Numerical claims are limited to source-supported values, including:

- H&P every 3–6 months for 1–2 years;
- H&P every 6–12 months for years 3–5;
- recurrence timing context described by NCCN;
- nutrient categories.

No unsupported numerical thresholds were introduced.

---

## 4.7 Adjacent PP Overlap Audit

**PASS**

### PP-0220 — Surveillance

Detailed surveillance ownership remains delegated.

### PP-0221 — Recurrence Detection

Recurrence detection is an interface only.

### PP-0217 — Response Assessment

Excluded.

### PP-0218 — RECIST

Excluded.

### PP-0219 — Post-treatment Imaging

Imaging is interface only.

### PP-0229 — Gastric Cancer Survivorship

PP-0230 owns longitudinal process; PP-0229 owns survivorship content.

### PP-0231 — Treatment-related Toxicity and Supportive Care

PP-0230 identifies and monitors long-term issues; detailed management is delegated.

### PP-0232 — Multidisciplinary Management

PP-0230 owns care-coordination interface; broader MDT architecture is delegated.

**No substantive duplicate ownership identified.**

---

## 4.8 Knowledge Graph Audit

**PASS**

The package defines:

### Prerequisites

Treatment-response, imaging, surveillance and recurrence context.

### Related

Survivorship, supportive care, toxicity and multidisciplinary care.

### Downstream

Survivorship and long-term supportive management.

The relationships are clinically meaningful and not artificial.

---

## 4.9 Clinical Safety Review

**PASS**

The package does not:

- diagnose recurrence;
- prescribe treatment;
- prescribe supplements;
- generate individualized surveillance;
- determine care-transfer timing;
- interpret individual test results.

It repeatedly preserves the need for individualized clinical assessment.

---

## 4.10 Patient Misconception Review

**PASS**

Potentially harmful misunderstandings are explicitly controlled.

Especially:

> “After five years all care ends.”

This is corrected using the NCCN distinction between routine gastric-cancer-specific surveillance and continued long-term care. fileciteturn40file4turn40file18

---

## 4.11 Cross-artifact Consistency

**PASS**

CKO, KP, EP and QA agree on:

- PP identity;
- scope;
- exclusions;
- evidence hierarchy;
- Knowledge Graph;
- boundary;
- safety constraints;
- version.

No contradictory package identity was identified.

---

## 4.12 Boundary Integrity

**PASS**

The four-part Boundary is consistent across the package:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

It preserves the primary ownership distinction:

> **PP-0230 = longitudinal follow-up process**

rather than:

> surveillance / recurrence / survivorship / toxicity.

---

## 4.13 Package Integrity

**PASS**

Required four artifacts are present and named according to project standards.

The ZIP filename includes:

- PP number;
- full title;
- GOLD;
- version.

---

# QA Findings

| QA Dimension | Result | Severity |
|---|---|---|
| Content completeness | PASS | None |
| Scope integrity | PASS | None |
| Clinical accuracy | PASS | None |
| Evidence traceability | PASS | None |
| Evidence maturity | PASS | None |
| Patient-facing clarity | PASS | None |
| Safety | PASS | None |
| Adjacent PP overlap | PASS | None |
| Knowledge Graph | PASS | None |
| Governance compliance | PASS | None |
| Gold depth | PASS | None |
| Cross-artifact consistency | PASS | None |
| Package integrity | PASS | None |

---

# Known Limitations

1. Some surveillance recommendations are supported primarily by retrospective evidence and expert consensus.
2. Exact individual follow-up plans are not determined by this PP.
3. Long-term follow-up requirements vary with treatment history, stage and patient-specific factors.
4. Detailed nutritional management remains delegated.
5. Detailed surveillance and recurrence detection remain delegated.

These are **known evidence/scope limitations**, not production blockers.

---

# QA Final Determination

## **PASS**

No critical clinical, educational, evidence, boundary, governance or package-integrity blocker identified.

## Gold Readiness

**READY FOR INTEGRATION**

---

# Final QA Status

**PASS — GOLD — READY FOR INTEGRATION.**
